| # | Title | Journal | Year | Citations |
|---|
| 1 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 2,545 |
| 2 | Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2018 | 1,571 |
| 3 | Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients | International Journal of Radiation Oncology Biology Physics | 2006 | 583 |
| 4 | Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 579 |
| 5 | Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab | Journal of Clinical Oncology | 2009 | 576 |
| 6 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2015 | 574 |
| 7 | A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma | Journal of the National Cancer Institute | 2005 | 567 |
| 8 | Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing | Clinical Chemistry | 2013 | 447 |
| 9 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial | Lancet Oncology, The | 2015 | 353 |
| 10 | Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus | International Journal of Cancer | 1999 | 341 |
| 11 | Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres | International Journal of Radiation Oncology Biology Physics | 1998 | 336 |
| 12 | Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors | International Journal of Radiation Oncology Biology Physics | 1995 | 297 |
| 13 | NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial | Lancet Oncology, The | 2019 | 288 |
| 14 | Intensity-modulated radiotherapy in nasopharyngeal carcinoma: dosimetric advantage over conventional plans and feasibility of dose escalation | International Journal of Radiation Oncology Biology Physics | 2003 | 279 |
| 15 | Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours | European Journal of Nuclear Medicine and Molecular Imaging | 1996 | 278 |
| 16 | FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer | Molecular Cancer | 2017 | 276 |
| 17 | A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma | International Journal of Radiation Oncology Biology Physics | 1995 | 270 |
| 18 | Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic Chemotherapy | Journal of Clinical Oncology | 2004 | 255 |
| 19 | Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial | Journal of Hepatology | 2013 | 254 |
| 20 | Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer | Annals of Oncology | 2014 | 246 |
| 21 | Scientific Advances in Lung Cancer 2015 | Journal of Thoracic Oncology | 2016 | 231 |
| 22 | Systemic treatment of hepatocellular carcinoma: An EASL position paper | Journal of Hepatology | 2021 | 217 |
| 23 | Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer | European Journal of Nuclear Medicine and Molecular Imaging | 1997 | 206 |
| 24 | Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease | | 2000 | 204 |
| 25 | How Successful Is High-Dose (≥60 GY) Reirradiation Using Mainly External Beams in Salvaging Local Failures of Nasopharyngeal Carcinoma? | International Journal of Radiation Oncology Biology Physics | 1998 | 198 |
| 26 | Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma | Future Oncology | 2011 | 191 |
| 27 | Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study) | Oral Oncology | 2018 | 189 |
| 28 | Human Breast Lesions: Characterization with Contrast-enhanced in Vivo Proton MR Spectroscopy—Initial Results | Radiology | 2001 | 179 |
| 29 | The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 | Journal of Thoracic Oncology | 2016 | 173 |
| 30 | High frequency of p16INK4A gene alterations in hepatocellular carcinoma | Oncogene | 1999 | 172 |
| 31 | Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group | Cancer | 2004 | 167 |
| 32 | Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study | Head and Neck | 2003 | 165 |
| 33 | Survival outcome of patients with nasopharyngeal carcinoma with first local failure: A study by the Hong Kong Nasopharyngeal Carcinoma Study Group | Head and Neck | 2005 | 157 |
| 34 | Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type | Cancer | 2003 | 154 |
| 35 | Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy | Annals of Oncology | 2004 | 153 |
| 36 | Preliminary results of trial NPC‐0501 evaluating the therapeutic gain by changing from concurrent‐adjuvant to induction‐concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma | Cancer | 2015 | 152 |
| 37 | Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions | Lung Cancer | 2018 | 131 |
| 38 | Azacitidine Induces Demethylation of the Epstein-Barr Virus Genome in Tumors | Journal of Clinical Oncology | 2004 | 129 |
| 39 | Nasopharyngectomy in the treatment of recurrent nasopharyngeal carcinoma: A twelve-year experience | | 2000 | 126 |
| 40 | Dysphagia in treated nasopharyngeal cancer | Head and Neck | 2000 | 125 |
| 41 | Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA | Journal of Clinical Oncology | 2004 | 125 |
| 42 | PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease | Journal of Gastroenterology and Hepatology (Australia) | 2015 | 125 |
| 43 | Cellular uptake, evolution, and excretion of silica nanoparticles in human cells | Nanoscale | 2011 | 121 |
| 44 | Measuring quality of life of Chinese cancer patients | Cancer | 2000 | 120 |
| 45 | Final report of a randomized trial on altered-fractionated radiotherapy in nasopharyngeal carcinoma prematurely terminated by significant increase in neurologic complications | International Journal of Radiation Oncology Biology Physics | 2000 | 120 |
| 46 | Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2010 | 120 |
| 47 | Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy | Annals of Surgical Oncology | 2008 | 117 |
| 48 | Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2014 | 114 |
| 49 | Analysis of Epstein–Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays | Journal of General Virology | 2006 | 113 |
| 50 | Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma | Cancer | 2005 | 112 |
